Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vital Farms Inc (VITL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vital Farms Inc — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B), while Vital Farms Inc trades at $9 (market cap $382.95M). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 19.2× Vital Farms Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vital Farms Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vital Farms Inc for 15 Days on average.
| SYRE | VITL | |
|---|---|---|
Market Cap | $7.35B | $382.95M |
Volume | 1,624,631 | 1,912,535 |
Sector | Health | Consumer Staples |
52-Week High | $108.92 | $40.85 |
52-Week Low | $22.18 | $8.28 |
Typical Hold Time | 0 Days | 15 Days |
Enterprise Value | $6.35B | $469.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Vital Farms (VITL) trades at $9.34, down 1.37% with bearish technical signals and mixed fundamentals. The company reported Q2 2026 revenue of $166 million (down 10.1% YoY) but beat expectations, while net income margins collapsed to near-zero levels. Recent news includes potential strategic options exploration and institutional buying activity despite challenging industry conditions.
The stock faces headwinds from egg pricing pressure and oversupply issues, though analyst consensus remains positive with a $13.11 price target. Key risks include margin compression and industry volatility, while potential upside exists from strategic alternatives and pasture-raised egg demand recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vital Farms Inc
Vital Farms is a leading provider of ethically produced, pasture-raised eggs and butter in the United States. Operating as a Public Benefit Corporation, it manages a network of over 650 family farms to deliver high-welfare food products. It leverages a scalable 'asset-light' partnership model that prioritizes transparency and animal welfare to meet the growing consumer demand for clean-label and sustainable food sources.
Read more on VITL →
